A Phase 1, Prospective, Randomized, Double Blind, Parallel, Placebo-Control, Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects
Latest Information Update: 06 Oct 2022
At a glance
- Drugs ZY 19489 (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors Zydus Lifesciences
Most Recent Events
- 08 Jul 2022 Status changed from recruiting to completed.
- 31 Jan 2022 New trial record